DuOtic enters the canine otitis externa market with a narrow safety frame
DuOtic, a veterinary otic gel containing terbinafine and betamethasone acetate, is labeled for the treatment of otitis externa in dogs associated with susceptible strains of yeast, specifically Malassezia pachydermatis. The product is a prescription animal drug and is restricted to use by or on the order of a licensed veterinarian. Its positioning is straightforward: treat an inflamed, yeast-driven ear canal while limiting the local inflammatory cascade that keeps the canal swollen, painful, and prone to recurrent infection.
The formulation contains 10 mg terbinafine and 1 mg betamethasone acetate per mL in an off-white to slightly yellow translucent gel. That pairing matters biologically because the antifungal component targets the organism burden, while the corticosteroid reduces edema, pruritus, and inflammatory thickening that can obstruct the external ear canal. In practical terms, a product like this is aimed at the common clinical loop in canine otitis externa: inflammation narrows the canal, moisture and debris accumulate, yeast proliferate, and the cycle continues unless both infection and inflammation are addressed together.
One dose is not the whole treatment plan.
Dosing depends on canal clearance, membrane integrity, and careful restraint
Administration is designed to be done by a veterinary professional. Before the first dose, the ear canal should be cleaned and dried, and the tympanic membrane must be verified as intact before each administration. The label instructs clinicians to administer one tube per affected ear, then repeat the dose in 7 days. After opening the tube by twisting the soft tip, the flexible tip is placed into the affected external ear canal and the entire contents are squeezed in. Gentle massage at the base of the ear follows so the gel can reach the lower portion of the canal.
The product also carries a very specific handling warning: restrain the dog to minimize head shaking after application, because splatter can occur and create accidental eye exposure in both people and dogs. Eye protection is recommended for the person administering the medication. The label further instructs that the ear canal should not be cleaned for 45 days after the initial administration so the gel remains in contact with the canal lining. If alternative otic therapy becomes necessary, the ear should be cleaned before that treatment is started.
Those instructions reflect the physical behavior of otic gels and the anatomy of the canine ear. A medicated gel can be effective only if it stays where the inflammation and yeast burden live. Head shaking, premature cleaning, or poor canal preparation can all reduce drug contact and undermine the intended local effect.
Tympanic perforation and ocular exposure define the most serious warnings
The label is unequivocal about several risks. DuOtic should not be used in dogs with known tympanic perforation, and it should not be used in dogs with hypersensitivity to terbinafine or corticosteroids. The integrity of the tympanic membrane should be confirmed before each dose because middle ear exposure changes the risk profile substantially. If hearing loss or signs of vestibular dysfunction appear during treatment, the dog should be reevaluated.
The caution is not theoretical. Changes to the middle ear, including ulceration of the mucosal lining, have been associated with administration of Osurnia, a product with the same concentrations of terbinafine and betamethasone acetate. Signs reported in relation to Osurnia include tympanic membrane rupture and internal ear disease such as head tilt, ataxia, nystagmus, facial paralysis, and keratoconjunctivitis sicca. DuOtic carries the same active ingredients at the same strengths, so the label carries those warnings forward in direct clinical terms.
Human safety warnings are equally direct. DuOtic may cause eye injury and irritation. If accidental eye contact occurs, the eyes should be flushed thoroughly with water for at least 15 minutes; contact lens wearers should rinse first, then remove lenses and continue rinsing. If symptoms develop, medical advice should be sought. The label also states plainly that the product is not for human use and that accidental ingestion or skin contact requires prompt washing or consultation as appropriate.
Liver enzymes, corticosteroid effects, and the limits of field safety data
The field study in dogs enrolled 120 animals in the DuOtic group and 119 in the control group. Adverse reactions were uncommon, but they were not absent. Elevated alanine aminotransferase occurred in 4 dogs treated with DuOtic, or 3.3%, and in none of the controls. Three of those dogs returned to normal on subsequent clinical chemistry testing, while one had no follow-up performed. Conjunctivitis was reported in 1 dog, ocular discharge in 1, ear discharge in none, and ear pruritus in 3 dogs treated with DuOtic.
The hepatic signal deserves attention because betamethasone, even when applied otically, is still a corticosteroid and can have systemic consequences under some conditions. The label warns that topical otic corticosteroids have been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs. DuOtic should be used with caution in dogs with impaired hepatic function. The safe use of the product has not been evaluated in pregnant, lactating, or breeding dogs, leaving those groups outside the studied margin of reassurance.
Post-approval experience adds neurologic and ocular caution from the class experience
Post-approval experience is drawn from adverse drug event reporting for Osurnia, not from direct DuOtic experience, but the label explicitly uses those data because the terbinafine and betamethasone acetate concentrations are identical. The reporting list in dogs includes deafness, ear discharge, pinnal irritation, ear pain, emesis, head shaking, internal ear disorder with head tilt and vestibular signs, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, nystagmus, tympanic rupture, and cranial nerve disorder including facial paralysis.
In humans, accidental exposure after a dog shook its head following application of Osurnia has been linked to corneal ulcers and other ocular injuries, including irritation, burning, stinging, and itchiness. Those events explain why DuOtic’s application instructions are so strict about eye protection, restraint, and post-application control. Ear medications can travel farther than intended when a painful or itchy dog reacts immediately after dosing.
The cat warning closes the door on extrapolation. DuOtic is for otic use in dogs only and should not be used in cats. The label also states that the product should not be administered orally. For clinicians, the practical message is simple: use the drug only when the external ear canal is the correct target, the tympanic membrane is intact, and the organism and inflammatory pattern match the product’s narrow design.